Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Leases (2020 - 2025)

Foghorn Therapeutics has reported Current Leases over the past 6 years, most recently at $923000.0 for Q4 2025.

  • Quarterly results put Current Leases at $923000.0 for Q4 2025, down 89.82% from a year ago — trailing twelve months through Dec 2025 was $923000.0 (down 89.82% YoY), and the annual figure for FY2025 was $923000.0, down 89.82%.
  • Current Leases for Q4 2025 was $923000.0 at Foghorn Therapeutics, down from $6.8 million in the prior quarter.
  • Over the last five years, Current Leases for FHTX hit a ceiling of $9.1 million in Q1 2025 and a floor of $923000.0 in Q4 2025.
  • Median Current Leases over the past 5 years was $6.9 million (2021), compared with a mean of $7.0 million.
  • Biggest five-year swings in Current Leases: soared 7582.42% in 2021 and later tumbled 89.82% in 2025.
  • Foghorn Therapeutics' Current Leases stood at $7.0 million in 2021, then fell by 14.64% to $6.0 million in 2022, then skyrocketed by 42.68% to $8.5 million in 2023, then increased by 6.45% to $9.1 million in 2024, then tumbled by 89.82% to $923000.0 in 2025.
  • The last three reported values for Current Leases were $923000.0 (Q4 2025), $6.8 million (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.